Circio (CRNA) Status update summary

Technology platform and innovation

• Proprietary circular RNA (circVec) platform enables enhanced and prolonged gene expression for gene and cell therapy applications.

• circVec delivers up to 75x longer half-life and 40x higher in vivo protein expression than conventional mRNA approaches.

• Demonstrated improved expression in heart, eye and CNS, including up to 40x increased activity in heart tissue.

• circVec can reduce AAV gene therapy doses, toxicity and cost while maintaining efficacy.

• In vivo cell therapy applications show >6 months of expression, outperforming mRNA approaches.

Market opportunity and partnerships

• Targeting genetic diseases affecting the heart, eye and CNS, as well as cancer and autoimmune disorders.

• Recent AAV gene therapy and in vivo cell therapy deals indicate commercial interest, with transactions up to $2.1 billion.

• First global pharma partnership entered in Q4 2025; additional collaborations targeted.

Rights issue and subscription

• Up to NOK 50m offered at NOK 1 per share; eligible holders receive 0.3481 rights per existing share, each entitling the holder to one offer share.

• NOK 24.2m in pre-subscriptions, including NOK 1.8m from board, management and employees, plus NOK 20m underwriting, secures NOK 44.2m or 88.4% of the maximum issue.

• Subscription runs 15–29 Jan 2026; rights trade on Euronext Oslo Børs 15–23 Jan under ticker CRNAT.

• Oversubscription and subscriptions without rights are permitted; unused or unsold rights lapse without compensation.

• Proceeds are expected to fund 12 months of operations and key pre-clinical milestones, including a feasibility study with a major pharma partner.